Friday 6 November 2026 Export ABBV’s income statement to Excel — free account

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue: +10.3%
EPS: +2,270.0%
Free cash flow: +9.97%
Total debt: +17.7%

Quarter to September 2026, against a year earlier

288.89 0.65 +0.23%

Follow ABBV

Alert me

Market cap: $509.5B
P/E: 49.7×
Fwd P/E: 38.6×
Dividend yield: 2.40%
F-score: 8/9
Altman Z: 2.31
Beneish M: −2.86
Dividend safety: 44/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

AbbVie Inc. (ABBV) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, AbbVie Inc. (ABBV) trades at a price to free cash flow of 27.1×. Over the past ten years it has ranged from 7.3× (August 2019) to 36.7× (January 2015); the current reading is higher than 96% of that period. That is above the Drug Manufacturers General industry median of 21.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ABBV/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="AbbVie Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ABBV/metrics/price-to-free-cash-flow">AbbVie Inc. (ABBV) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	22.7×	28.70%
FY2024	17.6×	37.64%
FY2023	12.8×	7.99%
FY2022	11.9×	8.82%
FY2021	10.9×	2.44%
FY2020	10.6×	3.62%
FY2019	10.3×	(7.58%)
FY2018	11.1×	(33.30%)
FY2017	16.7×	7.96%
FY2016	15.4×	12.22%

Period	Price to free cash flow	Change
Sep 2026	24.5×	0.31%
Jun 2026	24.4×	26.88%
Mar 2026	19.3×	(15.08%)
Dec 2025	22.7×	9.03%
43 more quarters	Free account

Against its own ten years

Low 7.3× High 36.7×

Ten-year median 13.4×

Current reading's percentile 96

Company	Price to free cash flow
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc. compare	15.5×
NVS Novartis AG compare	21.7×
MRK Merck & Co., Inc. compare	22.6×
ABBV AbbVie Inc.	27.1×
AMGN Amgen Inc. compare	27.3×
JNJ Johnson & Johnson compare	31.3×
AZN AstraZeneca PLC compare	45.8×
LLY Eli Lilly and Company compare	55.9×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

AbbVie Inc. (ABBV) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ABBV

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ABBV

Stockrow Weekly